Therapeutic drug monitoring of lacosamide as add-on treatment in a neonate with therapy-resistant epilepsy due to SCN2A mutation: a case report.

doi:10.1186/s13256-026-06255-w

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Therapeutic drug monitoring of lacosamide as add-on treatment in a neonate with therapy-resistant epilepsy due to SCN2A mutation: a case report.

Journal of medical case reports - 18 Jun 2026

Slikkerveer M, Hutten M C, Klinkenberg S, Knijnenburg A C S

Abstract excerpt

BACKGROUND: Lacosamide is registered for the treatment of (partial-onset) seizures in adults and children > 2 years of age, with a recommended maximum dose of 12 mg kg-1 in two doses. It is generally well tolerated. The use of lacosamide in neonates is off-label. We present the first case of a neonatal patient with refractory epilepsy who was started on lacosamide with monitoring of serial serum levels. CASE...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticonvulsants
Share to Drug Monitoring
Share to Drug Resistant Epilepsy
Share to Infant, Newborn

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Infant, Premature

Share to Mutation

Share to NAV1.2 Voltage-Gated Sodium Channel

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 42316283
DOI: 10.1186/s13256-026-06255-w
PMCID: PMC13520411

Genes

SCN2A

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.